Cost-effectiveness analysis of Helicobacter pylori screening

Abstract

Abstract: Introduction: Helicobacter pylori is an important risk factor for gastric cancer. This cancer has a significant impact on the quality of life and the performance of patients and couses high costs on the health care system. The main aim of this study was to assessment the cost-effectiveness Helicobacter pylori screening strategies in contrast to no screening and determine the most cost-effective strategy. Methods and Materials: This study is an economic evaluation. The usefulness and effectiveness of valid studies were obtained by reviewing the literature Direct medical data expenses of 1998 were Cost data collected retrospectively from patients' medical records and data from cost reimbursement. We used literature review to gain utility and effectiveness. In this study, we used tree age software and modeling methods such as decision tree and Markov model to analysis data. The health system perspective was considered for this study. Possible sensitivity analysis (PSA) was used to eliminate uncertainty. Results: According to QALY and the cost of screening tests serological, respiratory urea (UBT), stool (SAT) and endoscopy, that were 47.973, 47.98654, 47.98222, 47.982, 5938958, 673057, 5983148, 8647352 respectively, the cost-effectiveness ratio (ICER) was calculated. The results of this study showed that screening strategies were cost-effective in contrast to no screening, and non-invasive serological, respiratory urea (UBT) and stool (SAT) strategies were introduced as the dominant tests. The threshold in this study was determined based on the recommendations of the World Health Organization between 294432751 and 889298253. Conclusion: In this study, screening strategies were cost effective compared to no screening. The results show the economic justification of Helicobacter pylori screening in the Iranian population over 20 years.